Previous 10 | Next 10 |
5 Names For Your Penny Stocks List We’re kick-starting another week where penny stocks are at the center of attention. While economic data could fuel broader markets, sentiment and momentum seem to be carrying things forward for small-cap stocks. Premarket trading in benchmark ET...
Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models. SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, In...
LONDON, UK / ACCESSWIRE / March 11, 2021 / Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF) , is pleased to announce that all resolutions were duly passed at the General Meeting of the Company held today. Accordingly, as per the announcement of 19 February 2021, a total of 86,096,355 ordinary s...
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American A...
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to ...
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March. ...
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company en...
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...
Gainers: Ocugen OCGN +127%, CRH Medical CRHM +80%, Nemaura Medical NMRD +44%, aTyr Pharma (LIFE) +44%, Veru VERU +34%.Losers: ERYTECH Pharma ERYP -16%, Panbela Therapeutics (PBLA) -10%, Progenity PROG -9%, Ca...
Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...